After Falling 13% in the Last Month, Should You Scoop Up Shares of Bristol Myers Squibb?

This post was originally published on this site

Closing yesterday’s session at $60.15, the stock is trading 13.8% below the 52-week high of $69.75.

Though the stock’s price has dipped 13.1% over the past month, its impressive growth potential, significant clinical and regulatory milestones, and strategic collaborations with biopharmaceutical companies, including Pfizer , Inc. (NYSE:PFE), Otsuka Pharmaceutical Co., Ltd., and Bolt Biotherapeutics, Inc., are expected to boost its performance in the coming months. Furthermore, BMY’s robust product portfolio should help it achieve sustained growth.

Continue reading on StockNews

Add Comment